Clinical application of p2PSA and its derivatives (%p2PSA and Phi) in the diagnosis of prostate cancer

Clinical application of p2PSA and its derivatives (%p2PSA and Phi) in the diagnosis of prostate cancer

Bibliographic Details
Main Authors:	Weiwang Cai, Hewen Xu, Yan Shi
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	Asian Journal of Surgery
Subjects:	p2PSA Prostate health index(Phi) Prostate cancer(PCa) %p2PSA
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958423008527

Similar Items

Age-specific reference intervals for Prostate-Specific-Antigen (PSA), its isoform-[-2] pro-PSA (p2PSA) and prostate health index in Indian males
by: Govinda Raju NL, et al.
Published: (2024-04-01)

Utility of PSA isoform-[-2] proPSA (p2PSA) and prostate health index in the diagnosis of prostate cancer: A study in Indian population
by: Govinda Raju NL, et al.
Published: (2022-01-01)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
by: Tsung-Hsin Chang, et al.
Published: (2020-10-01)

Relation between Serum Level of Total PSA and Free PSA/Total PSA Ratio with Grade of Prostate Cancer
by: Mohammad Yazdani, et al.
Published: (2013-10-01)

The effect on the sensitivities of PSA and PSA-age volume score of IPSS and nocturia in predicting positive prostate biopsy findings
by: O. Üçer, et al.
Published: (2017-06-01)

Diagnostic value of free-to-total PSA proportion and PSA density in prostate cancer detection for prostate volumes >= 100 cc
by: Murat Zor, et al.
Published: (2018-12-01)

SIGNIFICANCE OF DETECTION OF FREE/TOTAL PSA RATIO AND OTHER BIOCHEMICAL PARAMETERS IN PATIENTS WITH BPH, CARCINOMA PROSTATE AND ITS CLINICOPATHOLOGIC CORRELATION
by: S. Joshi, et al.
Published: (2021-11-01)

Prostate – Specific Antigen (Psa) as a Screening Tool for Benign Prostate Hyperplasia (Bph) and Prostate Cancer (Pca) in Sulaimani Province
by: Sirwan M. Muhammad, et al.
Published: (2013-09-01)

Prognostic significance of Prostate-Specific Antigen (PSA) rate of change in patients with advanced prostate cancer
by: A E Aghaji, et al.
Published: (2005-01-01)

URINARY RETENTION EFFECT IN THE INCREASED OF PSA EXPRESSION WITHIN PROSTATIC TISSUE
by: Wahjoe Djatisoesanto, et al.
Published: (2015-10-01)

Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
by: Yiji Peng, et al.
Published: (2025-03-01)

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2
by: De Nitto Simone, et al.
Published: (2023-08-01)

Effect of urinary retention on the levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in prostatic disease
by: R Chawla, et al.
Published: (2003-01-01)

Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model
by: Francesco Gentile, et al.
Published: (2021-02-01)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
by: Michael H. Johnson, et al.
Published: (2015-09-01)

Understanding of PSA biology, factors affecting PSA detection, challenges, various biomarkers, methods, and future perspective of prostate cancer detection and diagnosis
by: Tasneem Khan, et al.
Published: (2022-10-01)

Serbest PSA/Total pSA Oranının Günlük Varyasyonu
by: Fatma Özdemir, et al.
Published: (2011-06-01)

General practitioners’ reflections on using PSA for diagnosis of prostate cancer. A qualitative study
by: Olav Thorsen, et al.
Published: (2022-04-01)

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report
by: Joan Manel Gasent Blesa, et al.
Published: (2009-04-01)

Management of a localized prostatic adenocarcinoma despite the very high rate of PSA and the large tumor mass: Does PSA level indicate the stage of prostate cancer?
by: Hammou el Farhaoui, et al.
Published: (2023-10-01)

Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden
by: Ulrika Rönningås, et al.
Published: (2019-07-01)

Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening
by: Ridwan Alam, et al.
Published: (2017-02-01)

Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators
by: Xiaomin Liu, et al.
Published: (2023-07-01)

Evaluation of serum PSA levels as a biomarker for breast carcinoma in north Indian females
by: Nikhil Gupta
Published: (2014-05-01)

Total PSA and free PSA in patients with severe liver dysfunction
by: Rama Devi Mittal, et al.
Published: (2003-01-01)

The effect of green tea on prostate specific antigen (PSA): A systematic review and meta-analysis of randomized controlled trials
by: Elham Sharifi-Zahabi, et al.
Published: (2021-03-01)

Preliminary effects of risk-adapted PSA screening for prostate cancer after integrating PRS-specific and age-specific variation
by: Xiaomin Liu, et al.
Published: (2024-08-01)

Prostate cancer in patients from rural and suburban areas – PSA value, Gleason score and presence of metastases in bone scan
by: Wojciech Szot, et al.
Published: (2014-11-01)

Towards personalized prostate cancer screening
by: Filella Xavier
Published: (2020-01-01)

Diagnostic accuracy of MRI-based PSA density for detection of prostate cancer among the Thai population
by: Chalida Aphinives, et al.
Published: (2023-01-01)

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
by: Zlata Huskova, et al.
Published: (2020-06-01)

Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuvant therapy before radical prostatectomy
by: Baruffi Marco, et al.
Published: (2004-04-01)

Comparative study of the values of transperineal and transrectal prostate puncture in diagnosis of prostate cancer in patients with gray/sub-gray zone of PSA
by: Wang Hailuo, Pang Kun, Wang Jingkai, Xu Peng, Xu Hao, Pan Deng, Ma Yuyang, Zhang Ruoran, Han Conghui
Published: (2024-02-01)

PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT
by: A. T. Asratov, et al.
Published: (2017-12-01)

A novel nomogram using PSA mass for predicting BPH
by: Hsiang Kai Ho, et al.
Published: (2023-12-01)

Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens
by: Nelson Gianni de Lima, et al.
Published: (2013-06-01)

Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, (68)Ga-PSMA PET/CT, PSA, and PSA-density comparison study
by: Hüseyin Akkaya, et al.
Published: (2023-09-01)

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review
by: Finn Edler von Eyben, et al.
Published: (2024-04-01)

Assessment of Atorvastatin Effectiveness on Serum PSA Level in Hypercholesterolemic Males
by: Darya Khosropanah, et al.
Published: (2011-12-01)

Assessment of Atorvastatin Effectiveness on Serum PSA Level in Hypercholesterolemic Males
by: Iradj Khosropanah, et al.
Published: (2011-12-01)